Examining the Interaction between Neurons and Cancer in the Pancreatic Cancer Microenvironment

Yang Chai^*
*Correspondence: Yang Chai, Department Pharmacology, Heidelberg University, Heidelberg, Germany, Email:

Introduction

Pancreatic cancer remains one of the most challenging and deadly malignancies, with a dismal prognosis and limited treatment options. The pancreatic tumor microenvironment plays a critical role in disease progression and resistance to therapy. Recent research has shed light on the complex interplay between cancer cells and various stromal components in the tumor microenvironment. Among these components, neurons have emerged as intriguing players with potential implications for both tumor biology and therapeutic strategies. This article delves into the interaction between neurons and pancreatic cancer cells within the tumor microenvironment. We explore the emerging evidence for the crosstalk between these two seemingly distinct cellular populations, and how it impacts cancer progression, immune responses, and potential therapeutic targets.

Pancreatic cancer is a formidable adversary in the realm of oncology, posing significant challenges to both clinicians and researchers. It is characterized by its high aggressiveness, late-stage diagnosis, and limited therapeutic options. The pancreas, a crucial organ in digestion and blood sugar regulation, consists of exocrine and endocrine components. The vast majority of pancreatic cancers, approximately 95%, originate from exocrine cells, mainly in the form of adenocarcinomas. In contrast, Neuroendocrine Tumors (NETs) comprise a smaller subset of pancreatic cancer cases. Despite advances in the understanding of cancer biology, the prognosis for pancreatic cancer remains grim. The five-year survival rate is typically less than 10%, primarily due to late-stage diagnosis and resistance to treatment. Pancreatic tumors are surrounded by a dense and highly complex microenvironment, consisting of stromal cells, extracellular matrix, blood vessels, and immune cells. This intricate milieu not only supports tumor growth and progression but also presents a significant barrier to effective treatment [1].

Pancreatic tumors are characterized by a prominent stroma, which can make up a substantial portion of the tumor mass. The stroma is composed of various cell types, including Cancer-Associated Fibroblasts (CAFs), immune cells, endothelial cells, and Extracellular Matrix (ECM) components. While these elements are not cancer cells per se, they actively participate in the tumorigenic process. CAFs, in particular, are key players in the stromal microenvironment of pancreatic cancer. They secrete growth factors, cytokines, and ECM proteins that provide structural support to the tumor. These CAFs can also promote Epithelial-Mesenchymal Transition (EMT), a crucial process that allows cancer cells to invade surrounding tissues and disseminate to distant sites [2-4].

In recent years, research has expanded beyond the traditional focus on cancer cells to include the tumor microenvironment and its role in cancer progression and resistance to therapy. One underexplored aspect of this microenvironment is the presence and function of neurons. Neurons are not typically associated with cancer, but growing evidence suggests that they can influence cancer behavior in several ways. Neurons release neuropeptides, which are small signaling molecules that play a role in neuronal communication. Some neuropeptides, such as substance P, Calcitonin Gene-Related Peptide (CGRP), and Neuropeptide Y (NPY), have been identified in the tumor microenvironment of various cancers, including pancreatic cancer. These neuropeptides can promote tumor growth, angiogenesis, and resistance to therapy.

Description

Neurons can also modulate the immune response within the tumor microenvironment. For instance, the release of neurotransmitters like norepinephrine and acetylcholine by sympathetic and parasympathetic neurons can affect the function of immune cells. This interaction can lead to immunosuppression, allowing cancer cells to evade the immune system. The peripheral nervous system provides a physical scaffold for pancreatic tumors. Tumor cells can infiltrate and co-opt nerves to facilitate their spread. This process, known as perineural invasion, is a common feature of pancreatic cancer and is associated with a poor prognosis. The nerves themselves may serve as conduits for the dissemination of cancer cells to distant sites.

The interaction between neurons and pancreatic cancer is a dynamic and multifaceted process that involves both chemical signaling and physical interactions. Several mechanisms have been proposed to explain how neurons influence the behavior of pancreatic cancer cells within the tumor microenvironment. Neuropeptides secreted by neurons, such as substance P and CGRP, can bind to receptors on pancreatic cancer cells. This binding can activate intracellular signaling pathways that promote cell proliferation, angiogenesis, and the production of pro-inflammatory cytokines. In this way, neuropeptides create a microenvironment conducive to tumor growth and immune evasion. Pancreatic cancer cells can undergo EMT, a process that enhances their invasive and metastatic potential. Nerves within the tumor microenvironment have been shown to induce EMT in cancer cells. This is believed to occur through the release of neuropeptides and other signaling molecules that activate EMT-related pathways. Perineural invasion is a unique feature of pancreatic cancer, wherein cancer cells infiltrate and wrap around nerves. This physical interaction can protect cancer cells from the immune system and serve as a conduit for metastasis. It is thought that the nerve microenvironment provides a nurturing environment for cancer cells. The release of neurotransmitters by nerves can affect the function of immune cells within the tumor microenvironment. Norepinephrine and acetylcholine, for example, can suppress the activity of immune cells, leading to immunosuppression. This creates a more favorable environment for tumor growth and progression [5].

Inhibition of neuropeptide signaling pathways, such as those involving substance P and CGRP, may offer a novel therapeutic approach. Blocking these pathways could disrupt the tumor-promoting effects of neurons and potentially enhance the response to standard cancer treatments. Given the role of nerves in perineural invasion and metastasis, surgical techniques that target nerves within and around the tumor could be explored. However, this approach must be carefully balanced with preserving critical nerve function for patients' quality of life. Understanding how neurotransmitters affect immune cell function could lead to strategies that reverse immunosuppression within the tumor microenvironment. Combining immune checkpoint inhibitors with therapies targeting neurotransmitter signaling might enhance the efficacy of immunotherapy in pancreatic cancer.

Conclusion

The presence and impact of neurons in the pancreatic tumor microenvironment may vary from patient to patient. Personalized medicine approaches could help identify patients who are more likely to benefit from therapies targeting neuronal interactions. Developing therapies that selectively target the interactions between neurons and cancer cells while sparing essential nerve functions is a significant challenge. Balancing the need to disrupt tumorpromoting interactions with preserving quality of life is essential. Identifying biomarkers that can accurately predict the impact of neuronal interactions in individual patients is crucial for personalized treatment strategies. More research is needed to establish reliable markers. Understanding the complex interplay between neurons, neurotransmitters, and the immune system is a formidable task. Research must unravel the precise mechanisms involved to develop effective immunomodulatory therapies. Optimal therapeutic strategies may involve combinations of treatments targeting different aspects of the neuronal-cancer interaction. The development of effective combination therapies requires rigorous preclinical and clinical testing.

Acknowledgement

None.

Conflict of Interest

There is no conflict of interest by author.

References

1. Rawla, Prashanth, Tagore Sunkara and Vinaya Gaduputi. "Epidemiology of pancreatic cancer: Global trends, etiology and risk factors." World J Oncol 10 (2019): 10.

Google Scholar, Crossref, Indexed at

2. D’Haese, Jan G., Mark Hartel, Ihsan Ekin Demir and Ulf Hinz, et al. "Pain sensation in pancreatic diseases is not uniform: The different facets of pancreatic pain." World J Gastroenterol 20 (2014): 9154.

Google Scholar, Crossref, Indexed at

3. Renz, Bernhard W., Takayuki Tanaka, Masaki Sunagawa and Ryota Takahashi, et al. "Cholinergic signaling via muscarinic receptors directly and indirectly suppresses pancreatic tumorigenesis and cancer stemness." Cancer Discov 8 (2018): 1458-1473.

Google Scholar, Crossref, Indexed at

4. Demir, Ihsan Ekin, Helmut Friess and Güralp O. Ceyhan. "Neural plasticity in pancreatitis and pancreatic cancer." Nat Rev Gastroenterol Hepatol 12 (2015): 649-659.

 Google Scholar, Crossref, Indexed at

5. Chatterjee, Deyali, Matthew H. Katz, Asif Rashid and Hua Wang, et al. "Perineural and intra-neural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma." Am J Surg Pathol 36 (2012): 409.

Google Scholar, Crossref, Indexed at